May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Histologic Changes After Intravitreal Injection of Rapamycin and Bevacizumab in a Porcine Model
Author Affiliations & Notes
  • E. Romo-Garcia
    Retina, APEC, Mexico, Mexico
  • D. Moreno-Páramo
    Retina, APEC, Mexico, Mexico
  • R. Velez-Montoya
    Retina, APEC, Mexico, Mexico
  • J. Flores-Estrada
    Retina, APEC, Mexico, Mexico
  • A. Hitos-Fajer
    Retina, APEC, Mexico, Mexico
  • E. Torres-Porras
    Retina, APEC, Mexico, Mexico
  • I. Hernández-Ayuso
    Retina, APEC, Mexico, Mexico
  • G. García-Aguirre
    Retina, APEC, Mexico, Mexico
  • A. Rodríguez-Reyes
    Retina, APEC, Mexico, Mexico
  • H. Quiroz-Mercado
    Retina, APEC, Mexico, Mexico
  • Footnotes
    Commercial Relationships  E. Romo-Garcia, None; D. Moreno-Páramo, None; R. Velez-Montoya, None; J. Flores-Estrada, None; A. Hitos-Fajer, None; E. Torres-Porras, None; I. Hernández-Ayuso, None; G. García-Aguirre, None; A. Rodríguez-Reyes, None; H. Quiroz-Mercado, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5622. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Romo-Garcia, D. Moreno-Páramo, R. Velez-Montoya, J. Flores-Estrada, A. Hitos-Fajer, E. Torres-Porras, I. Hernández-Ayuso, G. García-Aguirre, A. Rodríguez-Reyes, H. Quiroz-Mercado; Histologic Changes After Intravitreal Injection of Rapamycin and Bevacizumab in a Porcine Model. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5622. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To verify safety of intravitreal rapamycin, bevacizumab, and combination of both drugs studying histological changes in a porcine model.

Methods: : Eight eyes from a porcine model were included in this histologic study. The eyes were treated with 1ml intravitreal injection of bevacizumab (2.25mg/ml) in group A; intravitreal injection of balanced saline solution for group B (use as control) ; group C injected with 0.5ml of rapamycin (1mg/ml) in addition with a intravitreal injection of bevacizumab, and in group D rapamycin intravitreal injection alone. The eyes were enucleated 21 days after intravitreal injections, then tissue processing and stainig was performed with special dyes including hematoxylin and eosin, and Pearls stain.

Results: : No structural damage was detected or identified at any retinal layer of this porcine model of eyes injected with intravitreal rapamycin, bevacizumab, or even when including both drugs at the same time.

Conclusions: : Rapamycin is safe for intravitreal administration with no structural alterations and damage as reveal in the histologic findings of our study in a porcine model, neverless, we recommend electrofisiology testing and other safety-security evaluation methods before testing this drug intravitreously in humans.

Keywords: drug toxicity/drug effects • retina • clinical laboratory testing 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×